A Message from the ESMO President By Ogkologos - March 17, 2020 428 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Smoking Initiation Shifting from Teens to Young Adults November 6, 2020 What Do You Put In Your Pocket? April 28, 2021 Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma December 17, 2021 Research with integrity – the importance of communication November 14, 2022 Load more HOT NEWS How Some Brain Tumors Hijack the Mind to Grow Grief Anniversaries Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic...
